Claims:

1. Compounds of the general formula (I)



(I),

in which

R^{1a}, R^{1b} independently of one another represent H, C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, C_1-C_5-alkoxy-C_1-C_3-alkyl, C_3-C_6-cycloalkoxy-C_1-C_3-alkyl, amino-C_1-C_3-alkyl, C_1-C_5-alkylamino-C_1-C_3-alkyl, C_1-C_5-dialkylamino-C_1-C_3-alkyl or cyano, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, azetidine, pyrrolidine, piperazine and piperidine and where optionally present alkyl, cycloalkyl or heterocycloalkyl radicals can be mono- or polysubstituted, identically or differently by halogen, C_1-C_5-alkyl, hydroxyl, carboxyl, carboxy-C_1-C_5-alkyl, C_1-C_5-alkoxycarbonyl-C_1-C_5-alkyl or C_1-C_5-alkylsulphonyl,

R^4 represents H, F, Cl, C_1-C_2-alkyl, C_3-C_5-cycloalkyl, C_1-C_2-alkoxy or C_3-C_4-cycloalkylmethyl, where the corresponding alkyl or cycloalkyl unit can be mono- or polysubstituted, identically or differently by halogen or hydroxyl,

A represents $RO\text{-}CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0, 1, 2 or 3,

n is 0, 1, 2 or 3,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, Cl, CH_3, CF_3 CH_3O or CF_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, cyano, SF_5, C_1-C_3-alkyl, C_3-C_5-cycloalkyl, C_1-C_2-alkoxy or C_3-C_4-cycloalkylmethyl, where the corresponding alkyl or cycloalkyl unit can be mono- or polyhalogenated, and

R^9 represents C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_n$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, or C_1-C_7-alkoxy-C_2-C_5-alkyl, where the optionally present heterocyclic unit is selected from the group consisting of oxetane, tetrahydrofuran, tetrahydropyran, morpholine, pyrrolidine and piperidine and where the optionally present alkyl, cycloalkyl or heterocycloalkyl units can be mono- or polysubstituted, identically or differently by halogen, C_1-C_2-alkyl, C_1-C_2-alkoxy or carboxyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

2. Compounds according to Claim 1, where

R^{1a} represents H or C_1-C_5-alkyl,

R^{1b} represents H, C_1-C_5-alkyl, C_2-C_5-alkenyl, C_3-C_6-cycloalkyl-$(CH_2)_n$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, C_1-C_5-alkoxy-C_1-C_3-alkyl or C_1-C_5-dialkylamino-C_1-C_3-alkyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl- or cycloalkyl radicals can be

mono- or polysubstituted, identically or differently, by C_1-C_5-alkyl, hydroxyl, or C_1-C_5-alkylsulphonyl,

R^1 represents H, F, Cl, C_1-C_2-alkyl or C_1-C_2-alkoxy,

A represents $RO\text{-}CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, C_1-C_3-alkyl or C_1-C_2-alkoxy , and

R^9 represents C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_n$ or C_1-C_7-alkoxy-C_2-C_5-alkyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

3. Compounds according to Claim 1, where

R^{1a} represents H or methyl,

R^{1b} represents H, C_1-C_2-alkyl, vinyl, cyclopropyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, methoxy-C_1-C_2-alkyl or (N,N-dimethylamino)-methyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl or cycloalkyl radicals can be mono- or polysubstituted, identically or differently, by methyl, hydroxyl, or methylsulphonyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents RO-$CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

4. Compounds according to Claim 1, where

R^{1a} represents H or methyl,

R^{1b} represents H, C_1-C_2-alkyl, vinyl, cyclopropyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, methoxy-C_1-C_2-alkyl or (N,N-dimethylamino)-methyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl or cycloalkyl radicals can be mono- or polysubstituted, identically or differently, by methyl, hydroxyl, or methylsulphonyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents RO-$CO(CH_2)_p$, where R represents H,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

5. Compounds according to Claim 1, where

R^{1a} represents H,

R^{1b} represents methoxymethyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents $RO-CO(CH_2)_p$,
where R represents H,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

6. Compound according to Claim 1 selected from a group that contains the following compounds:

1. Methyl 1-allyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
2. 1-Allyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
3. Methyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylate
4. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
5. Methyl 1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
6. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
7. Methyl 4-chloro-1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
8. 4-Chloro-1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
9. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-methyl-1H-benzimidazole-5-carboxylic acid
10. 2-(9-Ethyl-7-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
11. 2-(9-Ethyl-5-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
12. 2-(9-Ethyl-8-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
13. 1-(Cyclopropylmethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
14. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-3-yl)-1H-benzimidazole-5-carboxylic acid
15. 2-(9-Ethyl-6-methoxy-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

16. 2-(9-Allyl-9H-carbazol-3-yl)-1-(cyclopropylmethyl)-1H-benzimidazole-5-carboxylic acid
17. 1-(Cyclopropylmethyl)-2-(9-methyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
18. 1-(Cyclopropylmethyl)-2-[9-(cyclopropylmethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
19. 2-[9-(Cyclopropylmethyl)-9H-carbazol-3-yl]-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
20. Ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole-5-carboxylate
21. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole-5-carboxylic acid
22. 2-(5-Ethyl-5H-pyrido[3,2-b]indol-2-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
23. 1-(Cyclopropylmethyl)-2-(9-ethyl-6-methoxy-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
24. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole-5-carboxylic acid
25. Ethyl-1-[2-(dimethylamino)ethyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
26. 1-[2-(Dimethylamino)ethyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
27. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-hydroxyethyl)-1H-benzimidazole-5-carboxylic acid
28. Ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1-isopropyl-1H-benzimidazole-5-carboxylate
29. 2-(9-Ethyl-9H-carbazol-3-yl)-1-isopropyl-1H-benzimidazole-5-carboxylic acid
30. 2-(9-Ethyl-9H-carbazol-3-yl)-1-methyl-1H-benzimidazole-5-carboxylic acid
31. Methyl 1-ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
32. 2-(9-Allyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
33. Ethyl 1-(2-methoxyethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylate
34. 1-(2-Methoxyethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
35. Ethyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(3-methoxypropyl)-1H-benzimidazole-5-carboxylate
36. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(3-methoxypropyl)-1H-benzimidazole-5-carboxylic acid
37. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-methoxy-1H-benzimidazole-5-carboxylic acid

38. 2-(9-Ethyl-9H-carbazol-3-yl)-6-methoxy-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

39. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-methoxy-1H-benzimidazole-5-carboxylic acid

40. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid

41. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-3-yl)-4-methyl-1H-benzimidazole-5-carboxylic acid

42. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-beta-carbolin-6-yl)-1H-benzimidazole-5-carboxylic acid

43. 1-(Cyclopropylmethyl)-2-(5-ethyl-5H-pyrido[4,3-b]indol-8-yl)-1H-benzimidazole-5-carboxylic acid

44. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-methyl-1H-benzimidazole-5-carboxylic acid

45. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-6-methyl-1H-benzimidazole-5-carboxylic acid

46. 2-(9-Ethyl-9H-carbazol-3-yl)-6-fluoro-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

47. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-fluoro-1H-benzimidazole-5-carboxylic acid

48. 2-(9-Ethyl-9H-carbazol-3-yl)-4-fluoro-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

49. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-fluoro-1H-benzimidazole-5-carboxylic acid

50. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-6-yl)-1H-benzimidazole-5-carboxylic acid

51. 1-(2-Cyclopropylethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

52. 1-(2-Methoxyethyl)-2-(9-propyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

53. 1-(2-Methoxyethyl)-2-[9-(prop-2-yn-1-yl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid

54. 1-(Cyclopropylmethyl)-2-(9-propyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

55. 1-[(2,2-Dimethylcyclopropyl)methyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

56. Ethyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(oxetan-3-ylmethyl)-1H-benzimidazole-5-carboxylate

57. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(oxetan-3-ylmethyl)-1H-benzimidazole-5-carboxylic acid

58. 2-[9-(Cyclobutylmethyl)-9H-carbazol-3-yl]-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

59. 2-[9-(Cyclobutylmethyl)-9H-carbazol-3-yl]-1-(cyclopropylmethyl)-1H-benzimidazole-5-carboxylic acid

60. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(trifluoromethoxy)ethyl]-1H-benzimidazole-5-carboxylic acid

61. 1-(Cyclopropylmethyl)-2-(9-ethyl-1-methyl-9H-beta-carbolin-3-yl)-1H-benzimidazole-5-carboxylic acid

62. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(oxetan-2-ylmethyl)-1H-benzimidazole-5-carboxylic acid

63. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(tetrahydrofuran-2-ylmethyl)-1H-benzimidazole-5-carboxylic acid

64. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[(2R)-2-hydroxy-3-methoxypropyl]-1H-benzimidazole-5-carboxylic acid

65. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[(2S)-2-hydroxy-3-methoxypropyl]-1H-benzimidazole-5-carboxylic acid

66. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(methylsulphonyl)ethyl]-1H-benzimidazole-5-carboxylic acid

67. 1-(2-Cyclopropyl-2-hydroxyethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

68. 1-[(2S)-2,3-Dihydroxypropyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

69. 1-(1,4-Dioxan-2-ylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

70. 1-(1,4-Dioxan-2-ylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid

71. 2-(9-Ethyl-6-methyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid

72. 2-(6-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid

73. 2-(8-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid

7. Compound of the formula (I), as defined in one of Claims 1 to 6, for the treatment and/or prophylaxis of diseases.

8. Compound of the formula (I), as defined in one of Claims 1 to 6, for use in a method for the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.

9. Use of a compound according to Claim 1, 2, 3, 4, 5 or 6 for the production of a medicament for the treatment and/or prophylaxis of diseases.

10. Use of a compound, such as defined in one of Claims 1 to 6, for the production of a medicament for the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.

11. Medicament containing a compound, such as defined in one of Claims 1 to 6, in combination with one or more further active substances, in particular with selective oestrogen receptor modulators (SERMs), oestrogen receptor (ER) antagonists, aromatase inhibitors, 17β-HSD1 inhibitors, steroid sulphatase (STS) inhibitors, GnRH agonists and antagonists, kisspeptin receptor (KISSR) antagonists, selective androgen receptor modulators (SARMs), androgens, 5α-reductase inhibitors, selective progesterone receptor modulators (SPRMs), gestagens, antigestagens, oral contraceptives, inhibitors of mitogen activated protein (MAP) kinases and inhibitors of MAP kinases kinases (Mkk3/6, Mek1/2, Erk1/2), inhibitors of protein kinases B (PKBα/β/γ; Akt1/2/3), inhibitors of phosphoinositide-3 kinases (PI3K), inhibitors of cyclin-dependent kinase (CDK1/2), Inhibitors of the hypoxia-induced signal pathway (HIF1alpha inhibitors, activators of the prolylhydroxylases), histone deacetylase (HDAC) inhibitors, prostaglandin F receptor (FP) (PTGFR) antagonists, neurokinin 1 receptor antagonists, paracetamol, selective COX2 inhibitors and/or non-selective COX1/COX2 inhibitors.

12. Medicament containing a compound of the formula (I) such as defined in one of Claims 1 to 6, in combination with an inert, non-toxic, pharmaceutically suitable excipient.

13. Medicament according to Claim 11 or 12 for the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.

Claims:

1. Compounds of the general formula (I)



(I),

in which

R^{1a}, R^{1b} independently of one another represent H, C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, C_1-C_5-alkoxy-C_1-C_3-alkyl, C_3-C_6-cycloalkoxy-C_1-C_3-alkyl, amino-C_1-C_3-alkyl, C_1-C_5-alkylamino-C_1-C_3-alkyl, C_1-C_5-dialkylamino-C_1-C_3-alkyl or cyano, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, morpholine, azetidine, pyrrolidine, piperazine and piperidine and where optionally present alkyl, cycloalkyl or heterocycloalkyl radicals can be mono- or polysubstituted, identically or differently by halogen, C_1-C_5-alkyl, hydroxyl, carboxyl, carboxy-C_1-C_5-alkyl, C_1-C_5-alkoxycarbonyl-C_1-C_5-alkyl or C_1-C_5-alkylsulphonyl,

R^4 represents H, F, Cl, C_1-C_2-alkyl, C_3-C_5-cycloalkyl, C_1-C_2-alkoxy or C_3-C_4-cycloalkylmethyl, where the corresponding alkyl or cycloalkyl unit can be mono- or polysubstituted, identically or differently by halogen or hydroxyl,

A represents RO-$CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0, 1, 2 or 3,

n is 0, 1, 2 or 3,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, Cl, CH_3, CF_3 CH_3O or CF_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, cyano, SF_5, C_1-C_3-alkyl, C_3-C_5-cycloalkyl, C_1-C_2-alkoxy or C_3-C_4-cycloalkylmethyl, where the corresponding alkyl or cycloalkyl unit can be mono- or polyhalogenated, and

R^9 represents C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_n$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, or C_1-C_7-alkoxy-C_2-C_5-alkyl, where the optionally present heterocyclic unit is selected from the group consisting of oxetane, tetrahydrofuran, tetrahydropyran, morpholine, pyrrolidine and piperidine and where the optionally present alkyl, cycloalkyl or heterocycloalkyl units can be mono- or polysubstituted, identically or differently by halogen, C_1-C_2-alkyl, C_1-C_2-alkoxy or carboxyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

2. Compounds according to Claim 1, where

R^{1a} represents H or C_1-C_5-alkyl,

R^{1b} represents H, C_1-C_5-alkyl, C_2-C_5-alkenyl, C_3-C_6-cycloalkyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, C_1-C_5-alkoxy-C_1-C_3-alkyl or C_1-C_5-dialkylamino-C_1-C_3-alkyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl- or cycloalkyl radicals can be

mono- or polysubstituted, identically or differently, by C_1-C_5-alkyl, hydroxyl, or C_1-C_5-alkylsulphonyl,

R^4 represents H, F, Cl, C_1-C_2-alkyl or C_1-C_2-alkoxy,

A represents $RO\text{-}CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, C_1-C_3-alkyl or C_1-C_2-alkoxy , and

R^9 represents C_1-C_5-alkyl, C_2-C_5-alkenyl, C_2-C_5-alkynyl, C_3-C_6-cycloalkyl-$(CH_2)_n$ or C_1-C_7-alkoxy-C_2-C_5-alkyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

3. Compounds according to Claim 1, where

R^{1a} represents H or methyl,

R^{1b} represents H, C_1-C_2-alkyl, vinyl, cyclopropyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, methoxy-C_1-C_2-alkyl or (N,N-dimethylamino)-methyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl or cycloalkyl radicals can be mono- or polysubstituted, identically or differently, by methyl, hydroxyl, or methylsulphonyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents $RO\text{-}CO(CH_2)_p$, where R represents H or C_1-C_2-alkyl,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



,

R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

4. Compounds according to Claim 1, where

R^{1a} represents H or methyl,

R^{1b} represents H, C_1-C_2-alkyl, vinyl, cyclopropyl-$(CH_2)_m$, C_3-C_6-heterocycloalkyl-$(CH_2)_n$, methoxy-C_1-C_2-alkyl or (N,N-dimethylamino)-methyl, where the optionally present heterocyclic unit is preferably selected from the group consisting of oxetane, tetrahydrofuran, 1,4-dioxane, morpholine and pyrrolidine and where optionally present alkyl or cycloalkyl radicals can be mono- or polysubstituted, identically or differently, by methyl, hydroxyl, or methylsulphonyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents RO-$CO(CH_2)_p$, where R represents H,

m is 0 or 1,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

5. Compounds according to Claim 1, where

R^{1a} represents H,

R^{1b} represents methoxymethyl,

R^4 represents H, F, Cl, methyl or methoxy,

A represents $RO\text{-}CO(CH_2)_p$,
where R represents H,

n is 0 or 1,

p is 0, and

B is selected from the following structures,



,

R^6 represents H, F, CH_3 or CH_3O,

R^7, R^8 in each case independently of one another represent H, F, Cl, methyl or methoxy, and

R^9 represents C_1-C_3-alkyl, allyl, propargyl, C_3-C_4-cycloalkyl-$(CH_2)_n$ or methoxyethyl,

and their isomers, diastereomers, enantiomers, solvates and salts or cyclodextrin clathrates.

6. Compound according to Claim 1 selected from a group that contains the following compounds:

1. Methyl 1-allyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
2. 1-Allyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
3. Methyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylate
4. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
5. Methyl 1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
6. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
7. Methyl 4-chloro-1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
8. 4-Chloro-1-(cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
9. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-methyl-1H-benzimidazole-5-carboxylic acid
10. 2-(9-Ethyl-7-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
11. 2-(9-Ethyl-5-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
12. 2-(9-Ethyl-8-fluoro-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
13. 1-(Cyclopropylmethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
14. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-3-yl)-1H-benzimidazole-5-carboxylic acid
15. 2-(9-Ethyl-6-methoxy-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid

16. 2-(9-Allyl-9H-carbazol-3-yl)-1-(cyclopropylmethyl)-1H-benzimidazole-5-carboxylic acid
17. 1-(Cyclopropylmethyl)-2-(9-methyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
18. 1-(Cyclopropylmethyl)-2-[9-(cyclopropylmethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
19. 2-[9-(Cyclopropylmethyl)-9H-carbazol-3-yl]-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
20. Ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole-5-carboxylate
21. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(pyrrolidin-1-yl)ethyl]-1H-benzimidazole-5-carboxylic acid
22. 2-(5-Ethyl-5H-pyrido[3,2-b]indol-2-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
23. 1-(Cyclopropylmethyl)-2-(9-ethyl-6-methoxy-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
24. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-benzimidazole-5-carboxylic acid
25. Ethyl-1-[2-(dimethylamino)ethyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
26. 1-[2-(Dimethylamino)ethyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
27. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-hydroxyethyl)-1H-benzimidazole-5-carboxylic acid
28. Ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1-isopropyl-1H-benzimidazole-5-carboxylate
29. 2-(9-Ethyl-9H-carbazol-3-yl)-1-isopropyl-1H-benzimidazole-5-carboxylic acid
30. 2-(9-Ethyl-9H-carbazol-3-yl)-1-methyl-1H-benzimidazole-5-carboxylic acid
31. Methyl 1-ethyl-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylate
32. 2-(9-Allyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
33. Ethyl 1-(2-methoxyethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylate
34. 1-(2-Methoxyethyl)-2-[9-(2-methoxyethyl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
35. Ethyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(3-methoxypropyl)-1H-benzimidazole-5-carboxylate
36. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(3-methoxypropyl)-1H-benzimidazole-5-carboxylic acid
37. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-methoxy-1H-benzimidazole-5-carboxylic acid

38. 2-(9-Ethyl-9H-carbazol-3-yl)-6-methoxy-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
39. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-methoxy-1H-benzimidazole-5-carboxylic acid
40. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid
41. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-3-yl)-4-methyl-1H-benzimidazole-5-carboxylic acid
42. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-beta-carbolin-6-yl)-1H-benzimidazole-5-carboxylic acid
43. 1-(Cyclopropylmethyl)-2-(5-ethyl-5H-pyrido[4,3-b]indol-8-yl)-1H-benzimidazole-5-carboxylic acid
44. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-methyl-1H-benzimidazole-5-carboxylic acid
45. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-6-methyl-1H-benzimidazole-5-carboxylic acid
46. 2-(9-Ethyl-9H-carbazol-3-yl)-6-fluoro-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
47. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-6-fluoro-1H-benzimidazole-5-carboxylic acid
48. 2-(9-Ethyl-9H-carbazol-3-yl)-4-fluoro-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
49. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-4-fluoro-1H-benzimidazole-5-carboxylic acid
50. 1-(Cyclopropylmethyl)-2-(9-ethyl-9H-pyrido[2,3-b]indol-6-yl)-1H-benzimidazole-5-carboxylic acid
51. 1-(2-Cyclopropylethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
52. 1-(2-Methoxyethyl)-2-(9-propyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
53. 1-(2-Methoxyethyl)-2-[9-(prop-2-yn-1-yl)-9H-carbazol-3-yl]-1H-benzimidazole-5-carboxylic acid
54. 1-(Cyclopropylmethyl)-2-(9-propyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
55. 1-[(2,2-Dimethylcyclopropyl)methyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
56. Ethyl 2-(9-ethyl-9H-carbazol-3-yl)-1-(oxetan-3-ylmethyl)-1H-benzimidazole-5-carboxylate

57. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(oxetan-3-ylmethyl)-1H-benzimidazole-5-carboxylic acid
58. 2-[9-(Cyclobutylmethyl)-9H-carbazol-3-yl]-1-(2-methoxyethyl)-1H-benzimidazole-5-carboxylic acid
59. 2-[9-(Cyclobutylmethyl)-9H-carbazol-3-yl]-1-(cyclopropylmethyl)-1H-benzimidazole-5-carboxylic acid
60. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(trifluoromethoxy)ethyl]-1H-benzimidazole-5-carboxylic acid
61. 1-(Cyclopropylmethyl)-2-(9-ethyl-1-methyl-9H-beta-carbolin-3-yl)-1H-benzimidazole-5-carboxylic acid
62. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(oxetan-2-ylmethyl)-1H-benzimidazole-5-carboxylic acid
63. 2-(9-Ethyl-9H-carbazol-3-yl)-1-(tetrahydrofuran-2-ylmethyl)-1H-benzimidazole-5-carboxylic acid
64. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[(2R)-2-hydroxy-3-methoxypropyl]-1H-benzimidazole-5-carboxylic acid
65. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[(2S)-2-hydroxy-3-methoxypropyl]-1H-benzimidazole-5-carboxylic acid
66. 2-(9-Ethyl-9H-carbazol-3-yl)-1-[2-(methylsulphonyl)ethyl]-1H-benzimidazole-5-carboxylic acid
67. 1-(2-Cyclopropyl-2-hydroxyethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
68. 1-[(2S)-2,3-Dihydroxypropyl]-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
69. 1-(1,4-Dioxan-2-ylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
70. 1-(1,4-Dioxan-2-ylmethyl)-2-(9-ethyl-9H-carbazol-3-yl)-1H-benzimidazole-5-carboxylic acid
71. 2-(9-Ethyl-6-methyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid
72. 2-(6-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid
73. 2-(8-Chloro-9-ethyl-9H-carbazol-3-yl)-1-(2-methoxyethyl)-4-methyl-1H-benzimidazole-5-carboxylic acid

7. Compound of the formula (I), as defined in one of Claims 1 to 6, for use in the treatment and/or prophylaxis of diseases.

8. Compound of the formula (I), as defined in one of Claims 1 to 6, for use in the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.

9. Use of a compound according to Claim 1, 2, 3, 4, 5 or 6 for the production of a medicament for the treatment and/or prophylaxis of diseases.

10. Use of a compound, such as defined in one of Claims 1 to 6, for the production of a medicament for the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.

11. Medicament containing a compound, such as defined in one of Claims 1 to 6, in combination with one or more further active substances, in particular with selective oestrogen receptor modulators (SERMs), oestrogen receptor (ER) antagonists, aromatase inhibitors, 17β-HSD1 inhibitors, steroid sulphatase (STS) inhibitors, GnRH agonists and antagonists, kisspeptin receptor (KISSR) antagonists, selective androgen receptor modulators (SARMs), androgens, 5α-reductase inhibitors, selective progesterone receptor modulators (SPRMs), gestagens, antigestagens, oral contraceptives, inhibitors of mitogen activated protein (MAP) kinases and inhibitors of MAP kinases kinases (Mkk3/6, Mek1/2, Erk1/2), inhibitors of protein kinases B (PKBα/β/γ; Akt1/2/3), inhibitors of phosphoinositide-3 kinases (PI3K), inhibitors of cyclin-dependent kinase (CDK1/2), Inhibitors of the hypoxia-induced signal pathway (HIF1alpha inhibitors, activators of the prolylhydroxylases), histone deacetylase (HDAC) inhibitors, prostaglandin F receptor (FP) (PTGFR) antagonists, neurokinin 1 receptor antagonists, paracetamol, selective COX2 inhibitors and/or non-selective COX1/COX2 inhibitors.

12. Medicament containing a compound of the formula (I) such as defined in one of Claims 1 to 6, in combination with an inert, non-toxic, pharmaceutically suitable excipient.

13. Medicament according to Claim 11 or 12 for use in the treatment and/or prophylaxis of endometriosis, of uterine leiomyomas, of uterine bleeding disorders, where the bleeding disorders can be severe and long-lasting bleeding, temporally irregular bleeding and pain, of dysmenorrhoea, of cancer, where the cancers can be lung, intestine, breast, skin, prostate, oesophageal cancer and leukaemia, of arteriosclerosis and of polycystic kidney diseases.